Chin Augmentation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Procedure (Surgical, Non-Surgical), By End-use (Cosmetic Surgery Center, Hospitals, MedSpas), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.71 Billion
CAGR (2026-2031)	6.68%
Fastest Growing Segment	Surgical
Largest Market	North America
Market Size (2031)	USD 2.52 Billion

Market Overview

The Global Chin Augmentation Market will grow from USD 1.71 Billion in 2025 to USD 2.52 Billion by 2031 at a 6.68% CAGR. Chin augmentation, clinically referred to as mentoplasty, is a surgical procedure designed to reshape or enhance the chin using implants or bone advancement techniques to improve facial harmony and proportion. The growth of this market is fundamentally supported by the increasing consumer prioritization of facial symmetry and the rising acceptance of aesthetic interventions among the male demographic, who frequently seek to define the jawline.

According to the American Society of Plastic Surgeons, in 2024, 5,529 chin augmentation procedures were performed by its member surgeons, reflecting the steady demand for this specific facial contouring surgery. Despite this consistent interest, the market faces a significant challenge regarding the high cost of the procedure and the potential risks of surgical complications, which can deter price-sensitive or risk-averse patients from pursuing treatment.

Key Market Drivers

Rising demand for minimally invasive and non-surgical dermal fillers is a primary catalyst propelling the market, as patients increasingly prioritize procedures with reduced downtime and lower risks compared to surgical mentoplasty. This shift is characterized by the widespread use of hyaluronic acid and calcium hydroxylapatite fillers to project and contour the chin, offering a reversible and adaptable alternative to permanent implants. The preference for these non-surgical "tweakments" significantly widens the addressable market beyond traditional surgical candidates. This trend is substantiated by global procedure volumes; according to the International Society of Aesthetic Plastic Surgery (ISAPS), June 2025, in the 'Global Survey on Aesthetic/Cosmetic Procedures', hyaluronic acid procedures increased by 5.2% worldwide, totaling approximately 6.3 million treatments, underscoring the dominance of injectable solutions in facial profiling.

Simultaneously, the market is expanding due to the increasing adoption of jawline contouring among the male demographic, driven by evolving aesthetic standards that equate a defined, strong jawline with fitness and executive presence. Men are becoming a critical consumer segment, actively seeking enhancements to improve facial structural balance and correct weak profiles without the stigma previously associated with cosmetic interventions. This demographic shift is highlighted by industry data; according to the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS), February 2025, in the '2024 Annual Trends Survey', 92% of surveyed surgeons reported treating male patients, reflecting a broadening patient base. Further demonstrating the financial scale of the sector supporting these procedures, according to Galderma, in 2025, the company achieved full-year 2024 Injectable Aesthetics net sales of 2,299 million USD.

Download Free Sample Report

Key Market Challenges

The high cost of chin augmentation stands as a formidable economic barrier restricting broader market expansion. Since mentoplasty is typically classified as an elective cosmetic procedure, it is generally excluded from medical insurance coverage, forcing patients to shoulder the entire financial burden independently. This pricing structure inherently limits the addressable market to high-income individuals, effectively pricing out a significant portion of the male and female demographics who prioritize facial symmetry but lack the disposable income for such discretionary spending. The substantial expenses involved often deter potential clients who might otherwise be motivated by the aesthetic benefits.

This financial challenge is substantiated by recent industry data highlighting the steep baseline costs. According to the American Society of Plastic Surgeons, in 2024, the average surgeon fee for chin augmentation was $3,641. It is crucial to note that this figure represents only the physician’s charge and excludes necessary facility fees, anesthesia, and medical tests, which can significantly increase the final price. Consequently, this cumulative financial weight acts as a direct brake on procedure volume growth globally, preventing the market from reaching its full potential among price-sensitive consumers.

Key Market Trends

The emergence of custom 3D-printed chin implants is revolutionizing the market by addressing the limitations of standard prosthetic shapes. Surgeons are increasingly utilizing computer-aided design (CAD) to fabricate patient-specific implants (PSIs) that match the unique bony anatomy of the recipient, ensuring superior contour adaptation and reducing the risk of implant migration. This technological evolution allows for the precise correction of asymmetry and microgenia without the extensive intraoperative shaping required by traditional porous polyethylene or silicone blocks. The commercial scalability of this personalized approach is evidenced by the financial growth of key enabling technology providers; according to Materialise, February 2025, in the 'Fourth Quarter and Full Year 2024 Results', revenue from the company's Medical segment increased by 14.8% for the full year 2024, underscoring the surging demand for personalized surgical solutions and 3D-printed medical devices.

Simultaneously, a distinct shift towards autologous fat grafting is reshaping procedure preferences as patients seek natural, biocompatible alternatives to synthetic materials. This technique involves harvesting adipose tissue from the patient's own body to augment the chin and jawline, offering the dual benefit of donor site contouring and the elimination of foreign body rejection risks associated with alloplastic implants. This trend is significantly amplified by the widespread usage of GLP-1 weight-loss medications, which often result in facial volume loss, driving individuals to choose restorative options that utilize their own biology to regain structural definition. This changing consumer preference is substantiated by recent clinical data; according to the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS), February 2025, in the '2024 Annual Trends Survey', facial plastic surgeons reported a 50% rise in the average number of fat grafting procedures performed over the preceding year.

Segmental Insights

The Surgical segment is currently positioned as the fastest growing category within the Global Chin Augmentation Market, primarily driven by a shifting consumer preference for permanent aesthetic solutions. Unlike non-invasive injectables that require frequent maintenance, surgical implants offer durable structural enhancements to facial symmetry and jawline definition. This growth is further accelerated by the availability of advanced biocompatible materials that meet the rigorous safety standards of regulatory bodies such as the U.S. FDA. Consequently, the assurance of long-term safety and the desire for lasting results are fueling the rapid expansion of surgical interventions.

Regional Insights

North America maintains a dominant position in the global chin augmentation market, primarily driven by the high volume of aesthetic procedures performed in the United States. This leadership is reinforced by established healthcare infrastructure and the local presence of major medical device manufacturers. The market benefits from rigorous safety standards enforced by the U.S. Food and Drug Administration, which facilitates consumer confidence in approved implants and injectable fillers. Furthermore, high disposable income levels enable broad access to various facial contouring treatments, sustaining the region's strong market performance.

Recent Developments

• In August 2025, Revance Therapeutics announced the U.S. launch of the Teoxane RHA Collection with Mepivacaine, marking a significant update to its line of resilient hyaluronic acid fillers used for dynamic facial correction. This launch introduced a new formulation replacing lidocaine with mepivacaine, an anesthetic intended to reduce vasodilation and potential bruising at the injection site while maintaining patient comfort. The updated collection includes formulations suitable for deep implantation and tissue support, which are essential for facial contouring procedures such as chin augmentation. The release followed FDA approval and aimed to improve the overall injection experience for both providers and patients.
• In September 2024, Allergan Aesthetics, an AbbVie company, announced that the China National Medical Product Administration (NMPA) approved Botox Cosmetic for the treatment of masseter muscle prominence in adults. This regulatory milestone established the product as the first neurotoxin approved in China for this specific indication, which addresses a wide or square lower face shape to create a slimmer and more defined jawline. The approval was based on a Phase 3 clinical trial where patients experienced a significant reduction in facial width compared to a placebo. This development expanded the company’s non-invasive facial contouring offerings in the key Asian aesthetic market.
• In June 2024, a pivotal study regarding the long-term safety and effectiveness of Radiesse (+) for jawline treatment was published in a prominent medical journal, highlighting research supported by Merz Aesthetics. The study evaluated the calcium hydroxylapatite injectable's performance in improving jawline contour, a critical aspect of lower face augmentation that complements chin definition. Results from the research indicated that the treatment provided clinically meaningful and durable improvements in jawline volume and contour through 60 weeks. The findings reinforced the product's safety profile and its efficacy in addressing lower face structural deficiencies without surgical intervention.
• In January 2024, Galderma received approval from Health Canada for Restylane SHAYPE, a new hyaluronic acid injectable specifically engineered for the temporary augmentation of the chin region. This product utilizes the company’s proprietary NASHA HD technology to create a firm gel with a high G-prime, designed to provide a bone-mimicking effect for shaping, projecting, and elongating the chin. The approval marked a significant expansion of the company's portfolio in the Canadian market, offering a non-surgical alternative to chin implants. Clinical studies supporting the launch demonstrated high patient satisfaction and natural-looking results sustained for up to 12 months.

Key Market Players

• New York Plastic Surgical Group
• Westlake Dermatology & Cosmetic Surgery
• Nazarian Plastic Surgery Inc.
• Ruby Surgery & Aesthetics
• Cadogan Clinics Limited
• UK Aesthetic Limited
• UK Healthcare Aesthetics Center
• Marroquin & Sandoval Plastic Surgery
• Advanced Cosmetic Surgery Limited
• Orange County Facial Plastic Surgery

By Procedure	By End-use	By Region
Surgical Non-Surgical	Cosmetic Surgery Center Hospitals MedSpas	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Chin Augmentation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Chin Augmentation Market, By Procedure:

• Surgical
• Non-Surgical

• Chin Augmentation Market, By End-use:

• Cosmetic Surgery Center
• Hospitals
• MedSpas

• Chin Augmentation Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE